News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
699,796 Results
Type
Article (40027)
Company Profile (247)
Press Release (659522)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204344)
Career Advice (2008)
Deals (35443)
Drug Delivery (95)
Drug Development (81250)
Employer Resources (172)
FDA (16200)
Job Trends (14863)
News (345610)
Policy (32580)
Tag
Academia (2561)
Accelerated approval (5)
Adcomms (21)
Allergies (85)
Alliances (49526)
ALS (88)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (125)
Approvals (16202)
Artificial intelligence (254)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11638)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (175)
Bladder cancer (80)
Brain cancer (27)
Breast cancer (279)
Cancer (2272)
Cardiovascular disease (174)
Career advice (1677)
Career pathing (30)
CAR-T (152)
Cell therapy (425)
Cervical cancer (20)
Clinical research (66118)
Collaboration (833)
Company closure (1)
Compensation (533)
Complete response letters (21)
COVID-19 (2588)
CRISPR (40)
C-suite (241)
Cystic fibrosis (100)
Data (2207)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (270)
Diagnostics (6371)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (99)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86663)
Editorial (37)
Employer branding (21)
Employer resources (146)
Events (112504)
Executive appointments (722)
FDA (17463)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (748)
Gene editing (104)
Generative AI (19)
Gene therapy (302)
GLP-1 (709)
Government (4420)
Grass and pollen (4)
Guidances (67)
Healthcare (18837)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (115)
Indications (29)
Infectious disease (2730)
Inflammatory bowel disease (138)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16519)
IRA (40)
Job creations (3633)
Job search strategy (1423)
Kidney cancer (10)
Labor market (38)
Layoffs (469)
Leadership (17)
Legal (7914)
Liver cancer (75)
Lung cancer (326)
Lymphoma (154)
Machine learning (7)
Management (58)
Manufacturing (306)
MASH (67)
Medical device (13377)
Medtech (13382)
Mergers & acquisitions (19469)
Metabolic disorders (685)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1913)
NextGen: Class of 2025 (6514)
Non-profit (4480)
Now hiring (39)
Obesity (364)
Opinion (204)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (84)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (112)
Peanut (46)
People (57336)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20628)
Phase II (29107)
Phase III (21673)
Pipeline (1204)
Policy (139)
Postmarket research (2571)
Preclinical (8792)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (378)
Real estate (5914)
Recruiting (65)
Regulatory (22323)
Reports (46)
Research institute (2326)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (69)
Series A (130)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3585)
State (2)
Stomach cancer (14)
Supply chain (68)
Tariffs (40)
The Weekly (29)
Vaccines (689)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (156)
Last 7 days (931)
Last 30 days (2627)
Last 365 days (32789)
2025 (10739)
2024 (35245)
2023 (40099)
2022 (51216)
2021 (55765)
2020 (54123)
2019 (46580)
2018 (35042)
2017 (32147)
2016 (31510)
2015 (37588)
2014 (31361)
2013 (26389)
2012 (28624)
2011 (29312)
2010 (27386)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (38020)
Australia (6243)
California (6135)
Canada (2016)
China (524)
Colorado (266)
Connecticut (274)
Delaware (148)
Europe (81553)
Florida (912)
Georgia (206)
Idaho (57)
Illinois (536)
India (25)
Indiana (308)
Iowa (11)
Japan (162)
Kansas (104)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (894)
Massachusetts (4568)
Michigan (220)
Minnesota (391)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1727)
New Mexico (28)
New York (1749)
North Carolina (967)
North Dakota (8)
Northern California (2682)
Ohio (204)
Oklahoma (14)
Oregon (34)
Pennsylvania (1378)
Puerto Rico (12)
Rhode Island (33)
South America (1097)
South Carolina (23)
South Dakota (1)
Southern California (2303)
Tennessee (101)
Texas (906)
United States (23130)
Utah (180)
Virginia (146)
Washington D.C. (62)
Washington State (551)
West Virginia (3)
Wisconsin (54)
699,796 Results for "anticancer inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BriaCell’s Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3
April 10, 2025
·
5 min read
Press Releases
MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO
March 20, 2025
·
4 min read
Biotech Beach
AntiCancer Inc. Has Received a New Patent That Revolutionizes Individualized Mouse Models of Human Cancer Patients by Increasing the Patient-tumor Establishment Rate in Mice to Close to 100%
AntiCancer Inc. announced it has just received US Patent 11,871,731 that describes a method to increase the rate of establishment of patient tumors in mice to close to 100%.
January 29, 2024
·
1 min read
Press Releases
J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics ‘JIN-A02' and ‘JIN-001' at AACR 2025
April 30, 2025
·
3 min read
Press Releases
Cybrexa Therapeutics Announces New Preclinical Data on Tumor-Selective Peptide-Drug Conjugates at ESMO Targeted Anticancer Therapies Congress 2025
March 4, 2025
·
4 min read
Press Releases
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
March 19, 2025
·
6 min read
Defence’s AccuTOX Published in the Prestigious Journal of Translational Medicine Its Peer Study with Preclinical Data on AccuTOX as an Anti-Cancer Molecule
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce the publication of a peer-reviewed study on the anticancer properties of its unconjugated AccuTOX®, one of Defence’s lead products engineered to treat established solid tumors.
June 6, 2024
·
6 min read
Defence’s ARM-X Anti-Cancer Vaccine Inhibits Growth of Pre-Established Ovarian Cancer Resulting in Complete Responses in Treated Animals
Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer vaccine is therapeutically effective against pre-established ovarian cancer (ID8 model) when combined with the anti-PD-1 immune-checkpoint inhibitor.
June 25, 2024
·
4 min read
Press Releases
ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo
January 14, 2025
·
3 min read
Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update
Defence Therapeutics Inc. is pleased to announce the publication of a peer-reviewed study on the anticancer properties of its dual Accum®-E7 vaccine, one of Defence’s experimental product designed to treat established cervical cancer.
March 1, 2024
·
5 min read
1 of 69,980
Next
